US2009291436A1PendingUtilityA1
Methods for detecting nucleic acids indicative of cancer
Est. expiryApr 9, 2019(expired)· nominal 20-yr term from priority
Inventors:Anthony P. Shuber
G01N 33/57565G01N 33/57535C12Q 1/6886
59
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The invention provides methods for screening tissue or body fluid samples for nucleic acid indicia of cancer or precancer.
Claims
exact text as granted — not AI-modified1 . A method for screening a patient for cancer or precancer, the method comprising the steps of:
detecting in a patient tissue or body fluid sample comprising exfoliated cells and cellular debris, nucleic acid fragments that are greater than 200 base pairs in length; the presence of said fragments being a positive screen for cancer or precancer.
2 . The method of claim 1 , wherein said detecting step comprises conducting an amplification reaction designed to amplify only nucleic acids in said sample that are greater than 200 base pairs in length.
3 . The method of claim 1 , wherein said sample is selected from the group consisting of stool, pus, and urine.
4 . The method of claim 1 , further comprising the step of enriching said sample for human DNA.
5 . The method of claim 1 , further comprising the step of isolating human DNA from said sample.
6 . A method for screening a patient for cancer or precancer, the method comprising the steps of:
determining in a patient tissue or body fluid sample a first amount of nucleic acid fragments greater than 200 base pairs in length; determining in said sample a second amount of nucleic acid fragments less than about 200 base pairs in length; determining a ratio between said first amount and said second amount; and identifying a positive screen if said ratios exceeds a threshold ratio for patients who do not have cancer or precancer.
7 . A method for screening a patient for cancer or precancer, the method comprising the step of
detecting in a patient tissue or body fluid sample comprising exfoliated cells a nucleic acid fragment of a length that is not expected to be present in said sample in a healthy patient; the presence of said fragment being a positive screen.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.